JPRN-jRCT1080222731未知Unknown
Specific post-marketing surveillance of garenoxacin (Geninax) Clinical efficacy and safety of garenoxacin in the treatment of legionella pneumonia
Toyama Chemical Co., Ltd.(Current FUJIFILM Toyama Chemical Co., Ltd.)0 个研究点目标入组 20 人开始时间: 2015年1月29日最近更新:
试验速览
- 阶段
- Unknown
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •Registered patients in Japanese Society of Chemotherapy the committee of evaluation of legionella pneumonia on or after May 7, 2008
排除标准
- •1.Patients with a history of hypersensitivity to any of the ingredients of this product or quinolone antibacterial agents.
- •2.Pregnant women or women who may become pregnant
- •3.Children
研究者
相似试验
已完成
不适用
Post-marketing surveillance for refractory uveoretinitis associated with Behcet's disease under Remicade treatmentBehcet's diseaseJPRN-UMIN000027733Mitsubishi Tanabe Pharma Corporation100
未知
Unknown
Specific post-marketing surveillance of pazufloxacin (Pasil), an injectable antimicrobialJPRN-jRCT1080222732Toyama Chemical Co., Ltd.(Current FUJIFILM Toyama Chemical Co., Ltd.)300
招募中
不适用
Prospective, Post Marketing Surveillance of CAROGRA Tabletslcerative colitisD003093JPRN-jRCT2031220193Arai Yuki300
已完成
4 期
A post marketing study to check safety of Garenoxacin in patients with bacterial respiratory infectioCTRI/2015/01/005354Glenmark Pharmaceuticals Ltd461
未知
Unknown
Post-marketing surveillance of administration of botulinum toxin type B(NerBloc)-investigation of the clinical condition in patients with changing from botulinum toxin type Acervical dystoniaJPRN-jRCT1080222128Eisai Co., Ltd.150